NEPA (300mg netupitant/0.5mg palonosetron)

DRUG2 trials

Sponsors

Helsinn Healthcare SA, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions

Chemotherapy-induced Nausea and VomitingEndometrial Cancer

Phase 4

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

CompletedNCT04817189

Helsinn Healthcare SAChemotherapy-induced Nausea and Vomiting

Start: 2021-02-01End: 2024-07-02Updated: 2025-12-02

Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

RecruitingNCT06726291

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoEndometrial Cancer

Start: 2024-02-26End: 2026-06-30Target: 84Updated: 2024-12-10